

## MONOFER® (IRON ISOMALTOSIDE) TO LAUNCH IN MALAYSIA

Compai Pharma and Pharmacosmos announce their partnership to launch MonoFer®, an innovative parenteral iron formulation for the treatment of iron deficiency, by the end of 2018.

Compai Pharma has been granted exclusive rights to market, distribute and sell iron isomaltoside in Malaysia, and will promote the brand through its own medical and sales team across the country.

### *About Iron Deficiency*

Iron deficiency is a health-related condition in which iron availability is insufficient to meet the body's needs and negatively impacting one's quality of life. It can be present with or without anaemia. Patients with iron deficiency may suffer from symptoms like fatigue, headache, hair-loss, shortness of breath and/or abnormal heartbeat caused by vital processes being compromised by the low iron levels and impaired energy generation in cells. It is commonly associated with various conditions such as certain gynaecological diseases (heavy menstrual bleedings and post-partum haemorrhages) as well as gastrointestinal bleedings, chronic heart failure and other relevant diseases.

The structure of MonoFer® is designed to be different from other intravenous iron replacement therapies allowing the possibility to administer high doses of iron, often in only one visit to the doctor, for the benefit and convenience of patients, healthcare professionals and hospital budgets.

Iron deficiency, with and without anaemia, is important across many conditions including for patients planned for surgery (or those with high blood loss during surgery) where early correction of iron levels may reduce blood transfusion requirements; for pregnant women, especially in the 3<sup>rd</sup> trimester, where iron therapy reduces the potential of negative outcomes for both mother and baby; whilst in the setting of chronic heart failure, correcting iron deficiency has been demonstrated to improve quality of life and may also reduce morbidity and mortality.

It is estimated that up to 1 in 3 women of child-bearing age and nearly 1 in 2 adults over 55 years of age may be suffering, many unknowingly, from iron deficiency - making it one of the most common nutritional deficiencies.

"We are excited to launch MonoFer® in Malaysia. By making this product available we believe that many more patients suffering from iron deficiency will now be able to receive treatment and have iron correction in just one visit" says Tim Cushway, CEO Compai Pharma.

---



## ABOUT MONOFER®

MonoFer® (iron isomaltoside 1000 for injection) is an iron-carbohydrate complex for intravenous administration. Clinical trials with MonoFer® have involved more than 6,000 patients. MonoFer® is now marketed in more than 30 countries with more than 10 million doses administered worldwide for the treatment of iron deficiency and iron deficiency anaemia.

MonoFer® is manufactured by Pharmacosmos A/S, Denmark.

---

## ABOUT COMPai PHARMA

Compai Pharma ([www.compaipharma.com](http://www.compaipharma.com)) was founded in Singapore and registered its Malaysian subsidiary in 2017. The growing team of medical and pharmaceutical experts are passionate about going the extra mile to ultimately achieve the best patient outcome. “Compai” means friend and the company strives to improve the lives of patients by providing access to essential products and medical devices.

---

## ABOUT PHARMACOSMOS A/S

Pharmacosmos A/S is a family-owned Danish pharmaceutical company headquartered in Holbæk, Denmark. The company was founded in 1965 and today sells its products in the UK, Scandinavia and Germany through its own subsidiaries and across the world through partners. Pharmacosmos is a global leader in the development and marketing of medicines for the treatment of iron deficiency and iron deficiency anaemia. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with an unrivalled expertise in the synthesis of iron-carbohydrate complexes to bring better treatments for patients suffering from iron deficiency. The state-of-the-art facilities in Denmark are approved by both the Danish Medicines Agency and the US Food & Drug Administration.

**References:** 1) *Iron Deficiency Anaemia Assessment and Control*. WHO/NHD/01.3. 2) Fonseca. *Intern Med J*. 2016;46:470-8. 5. Yeo. *Eur J Heart Fail*. 2014;16:1125-32. 3) Camaschella. *N Engl J Med*. 2015;372:1832-1843. 4) Munoz et al. *J Hematol Blood Transfus*. 2017;15:422-437. 5) Abeyisiri et al. NATA. 2018, Poster 49. 6) Auerbach. *Repro Health*. 2018;15(Suppl 1):96.

Contact for media enquiries: [heikecushway@tis-health.com](mailto:heikecushway@tis-health.com)